Across TCGA pan-cancer cohorts, COX5A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated COX5A data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher COX5A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated COX5A expression acts as an unfavorable survival marker.
ESCA and BRCA are the cancer types where COX5A Mutation most reproducibly stratifies survival.